Table 1. Patient characteristics and P-values for DFS and OS in the univariate analyses.
| Characteristic | Value | N = 141N (%) | 5 year DFS(%) (DFS time range) | DFS P-value | 5 year OS(%) (OS time range) | OS P-value |
| Sex | Male | 72 (51.1) | 71.1 (1 to 135) | 0.817 | 88.9 (2 to 142.4) | 0.722 |
| Female | 69 (48.9) | 79.3 (3 to 126) | 87.4 (2 to 144) | |||
| Median age (range) | 32 (13–89) | |||||
| <45 | 110 (78) | 77.9 (1 to 135) | 0.100 | 95.7 (9 to 143) | <0.001 | |
| ≥45 | 31 (22) | 64.7 (3 to 91) | 61 (2 to119) | |||
| Histology | Nodular sclerosis | 83 (58.9) | 77.2 (1 to 135) | 0.478 | 95.1 (9 to 144) | 0.001 |
| Other | 58 (41.1) | 72.4 (1 to 106) | 78.5 (2 to 120) | |||
| B symptoms | Yes | 59 (41.8) | 69.4 (1 to 104) | 0.470 | 75.6 (2 to 127) | <0.001 |
| No | 82 (58.2) | 78.6 (3 to 135) | 92.7 (11 to 144) | |||
| Bulky mass | Yes | 29 (20.6) | 84.4 (4 to 111) | 0.239 | 90.4 (11 to | 0.298 |
| No | 112 (79.4) | 72.8 (1 to 135) | 127)86.3 (2 to 144) | |||
| Anemia, Hb levels less than 105 g/L | Yes | 31 (22) | 60 (1 to 77) | 0.091 | 70.4 (2 to 127) | <0.001 |
| No | 110 (78) | 79.2 (1 to 135) | 93.4 (9 to 144) | |||
| Leukocytosis, more than 15×109/L | Yes | 17 (12.1) | 75 (2 to 82) | 0.987 | 88.2 (10 to 92) | 0.287 |
| No | 124 (87.9) | 75.9 (1 to 135) | 88.4 (2 to 144) | |||
| Lymphocytopenia, <0.6×109/L or <8% of WBC | Yes | 17 (12.1) | 57.1 (1 to 78) | 0.642 | 68.8 (2 to 119) | 0.003 |
| No | 124 (87.9) | 77.6 (1 to 135) | 90.7 (2 to 144) | |||
| Hypoalbuminemia, <40 g/L | Yes | 46 (32.6) | 77.6 (1 to 126) | 0.656 | 70.7 (2 to 142) | <0.001 |
| No | 86 (60.9) | 73.2 (1 to 135) | 94.3 (9 to 144) | |||
| High LDH level, >450 UI/L | Yes | 40 (28.4) | 64.6 (1 to 106) | 0.321 | 78.6 (2 to 119) | 0.021 |
| No | 99 (70.2) | 78.6 (1 to 135) | 92.1 (2 to 144) | |||
| High B-2-microglobulin level,>25 mg/L | Yes | 27 (19.1) | 73.1 (1 to 104) | 0.974 | 68.2 (2 to 112) | <0.001 |
| No | 84 (60) | 72.6 (1 to 135) | 94.9 (9 to 144) | |||
| Stage | early (I–II) | 86 (61) | 78.5 (1 to 126) | 0.148 | 96.7 (3 to 142) | <0.001 |
| advanced (III–IV) | 54 (38.6) | 68 (1 to 134) | 74.2 (2 to 144) | |||
| EBV | Positive | 40 (38.1) | 50.8 (1 to 90) | 0.480 | 75 (2 to 106) | 0.120 |
| Negative | 65 (46.1) | 69.9 (1 to 90) | 87.9 (2 to 100) | |||
| Unknown | 36 (15.8) | |||||
| Treatment | ABVD | 73 (52.1) | 60.6 (1 to 109) | 0.265 | 95.7 (2 to 116) | 0.221 |
| MOPPABV | 53 (37.9) | 77.9 (1 to 135) | 86.1 (2 to 145) | |||
| MOPP | 8 (5.7) | 100 (26 to 120) | 85.7 (3 to 142) | |||
| Other | 7 (4.3) | 25 (2 to 19) | ||||
| Toxicities | Neutropenia | 47 (33.3) | 77.9 (3 to 104) | 0.473 | 79.6 (1–112) | 0.018 |
| Anemia | 6 (4.3) | 66.7(3 to 91) | 0.375 | 33.3 (2 to 99) | <0.001 | |
| Thrombocytopenia | 6 (4.3) | 66.7 (3 to 91) | 0.658 | 44.4 (2 to 99) | 0.001 | |
| Pulmonary toxicity | 7 (5) | 68.6 (3 to 88) | 0.464 | 85.7 (16 to106) | 0.889 | |
| Neurological toxicity | 23 (16.3) | 71 (6 to 113) | 0.729 | 95.2 (19 to135) | 0.169 | |
| Infectious toxicity | 51 (36.2) | 80 (3 to 113) | 0.375 | 80 (1 to 123) | 0.019 |